The Role of Ruxolitinib in Myeloproliferative Neoplasms

Jorge E. Cortes, MD, explains how ruxolitinib is used to treat various myeloproliferative neoplasms and which patients require other therapies.

Jorge E. Cortes, MD, director, Georgia Cancer Center, Augusta University, explains how ruxolitinib (Jakafi) is used to treat various myeloproliferative neoplasms and which patients require other therapies.

Ruxolitinib is very effective in myelofibrosis, particularly for patients who have a large spleen size or are symptomatic. Since ruxolitinib does not cure the disease, patients without these issues do not have the same benefit.

Ruxolitinib is also approved for the treatment of polycythemia vera and essential thrombocythemia for patients who have not responded to initial therapy and for whom few options are available.

<< View more from the 24th Annual International Congress on Hematologic Malignancies